GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » ROC %

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) ROC % : 22.23% (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Dawnrays Pharmaceutical (Holdings)'s annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 22.23%.

As of today (2025-03-15), Dawnrays Pharmaceutical (Holdings)'s WACC % is 5.69%. Dawnrays Pharmaceutical (Holdings)'s ROC % is 15.08% (calculated using TTM income statement data). Dawnrays Pharmaceutical (Holdings) generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Dawnrays Pharmaceutical (Holdings) ROC % Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) ROC % Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.40 18.07 17.52 15.88 15.30

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.84 16.59 24.79 7.08 22.23

Dawnrays Pharmaceutical (Holdings) ROC % Calculation

Dawnrays Pharmaceutical (Holdings)'s annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=483.799 * ( 1 - 22.07% )/( (2576.827 + 2352.103)/ 2 )
=377.0245607/2464.465
=15.30 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4101.294 - 617.764 - ( 1108.941 - max(0, 1040.842 - 1947.545+1108.941))
=2576.827

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3962.388 - 460.443 - ( 1166.731 - max(0, 731.672 - 1881.514+1166.731))
=2352.103

Dawnrays Pharmaceutical (Holdings)'s annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=612.788 * ( 1 - 11.71% )/( (2352.103 + 2516.348)/ 2 )
=541.0305252/2434.2255
=22.23 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3962.388 - 460.443 - ( 1166.731 - max(0, 731.672 - 1881.514+1166.731))
=2352.103

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4354.127 - 508.051 - ( 1329.728 - max(0, 706.054 - 2401.278+1329.728))
=2516.348

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Dawnrays Pharmaceutical (Holdings)'s WACC % is 5.69%. Dawnrays Pharmaceutical (Holdings)'s ROC % is 15.08% (calculated using TTM income statement data). Dawnrays Pharmaceutical (Holdings) generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Dawnrays Pharmaceutical (Holdings) ROC % Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Li Kei Ling
Hung Yung Lai
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines